Bionano Genomics raises $10M via registered direct offering of common stock and warrants at $1.145/share

Bionano Genomics, Inc.

Issues 8.73M shares (or equivalents) and warrants to purchase 8.73M shares at $1.02; exercise price $1.02, 5-year term.
Gross proceeds ~$10M; net proceeds for working capital, R&D, debt repayment, and capex.
Expected closing on April 8, 2024; H.C. Wainwright acts as sole placement agent with 6% cash fee.
Offered under effective shelf registration statement (File No. 333-270459); warrants include beneficial ownership limitations of 4.99%/9.99%.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Bionano Genomics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.0 million (effective 2024-04-04).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $10.0 million
Effective: 2024-04-04

Exact text from the filing

On April 4, 2024, Bionano Genomics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Registered Direct Offering”): (i) an aggregate of 6,536,682 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to an aggregate of 2,196,944 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 8,733,626 shares of Common Stock (the “Warrants”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-018181

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.